Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Blood (2022) 140 (Supplement 1): 1485–1487.

https://doi.org/10.1182/blood-2022-157399

Published: 2022

Journal Articles

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Cyril Quivoron, Helene Lecourt, Jean-Marie Michot, Julien Lazarovici, Julien Rossignol, David Ghez, Veronique Vergé, Veronique Saada, Alina Danu, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2021-149369

Published: 2021

Journal Articles

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Blood (2020) 136 (20): 2290–2295.

https://doi.org/10.1182/blood.2020008423

Published: 2020

Includes: Supplemental data

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)

Blood (2018) 132 (Supplement 1): 3152.

https://doi.org/10.1182/blood-2018-99-112654

Published: 2018

Journal Articles

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

David Ghez, Anne Calleja, Caroline Protin, Marine Baron, Marie-Pierre Ledoux, Gandhi Damaj, Mathieu Dupont, Brigitte Dreyfus, Emmanuelle Ferrant, Charles Herbaux, Kamel Laribi, Ronan Le Calloch, Marion Malphettes, Franciane Paul, Laetitia Souchet, Malgorzata Truchan-Graczyk, Karen Delavigne, Caroline Dartigeas, Loïc Ysebaert

Blood (2018) 131 (17): 1955–1959.

https://doi.org/10.1182/blood-2017-11-818286

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

Timothy Brighton, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, David Ghez, Brendan M. Weiss, MD, Andreas Kirsch, Hila Magen, MD, Mercedes Gironella, Dra., Albert Oriol, MD, Matthew Streetly, BMBS, MRCP, MRCPath, Xiang Qin, Rajesh Bandekar, Peter Hu, Ming Qi, MD PhD, Sepideh Nemat, MD PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3155.

https://doi.org/10.1182/blood.V130.Suppl_1.3155.3155

Published: 2017

Journal Articles

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Riwa Sakr, MD, Sylvain Pilorge, MD, Stephane De Botton, Claude Chahine, MD, Tereza Coman, MD PhD, Marcel Adler, MD, Jean-Baptiste Micol, MD PhD, Florence Pasquier, MD PhD, Christophe Willekens, MD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Eric Solary, MD, Vincent Ribbag, Jean-Henri Bourhis, Cristina Castilla-LLorente, MD PhD

Blood (2017) 130 (Supplement 1): 5544.

https://doi.org/10.1182/blood.V130.Suppl_1.5544.5544

Published: 2017

Journal Articles

B-Cell Prolymphocytic Leukemia, a Rare Lymphoproliferative Disorder: Analysis of 35 Cases, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Caroline Algrin, Elise Chapiro, Justine Saviellis, Anne Quinquenel, Anne-Sophie Michallet, MD PhD, David Ghez, MD PhD, Pierre Feugier, MD, Annie Brion, Cecile Tomowiak, MD, Luc-Matthieu Fornecker, Remy Gressin, MD, Laurent Sutton, MD, Karim Maloum, Catherine Settegrana, Lucile Baseggio, MD, Quentin Vincent, Florence Nguyen-Khac, MD PhD, Véronique Leblond

Blood (2017) 130 (Supplement 1): 4310.

https://doi.org/10.1182/blood.V130.Suppl_1.4310.4310

Published: 2017

Journal Articles

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Yolla EL Dakdouki, Jean-Marie Michot, MD, Julien Lazarovici, MD, Khalil Saleh, MD, David Ghez, MD PhD, Claude Chahine, MD, Loic Verlingue, Christophe Willekens, MD, Veronique Vergé, Christophe Ferme, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2017) 130 (Supplement 1): 2847.

https://doi.org/10.1182/blood.V130.Suppl_1.2847.2847

Published: 2017

Journal Articles

Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma

Layal el Halabi, Julien Adam, Virginie Marty, Jacques Bosq, MD, Julien Lazarovici, MD, Alina Danu, MD, Vincent Ribrag, MD, David Ghez, PhD MD

Blood (2016) 128 (22): 2952.

https://doi.org/10.1182/blood.V128.22.2952.2952

Published: 2016

Journal Articles

Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

Khalil Saleh, MD, Jean-Marie Michot, MD, Alina Danu, MD, Julien Lazarovici, MD, Nadine Khalifé-Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Yolla Dakdouki, MD, Jonathan Fahri, Resident, Christophe Willekens, MD, Angela Boros, MD, Julia Arfi-Rouche, MD, Pierre Maroun, MD, Eric Deutsch, PhD MD, Vincent Ribrag, MD, Renaud Mazeron, MD

Blood (2016) 128 (22): 1784.

https://doi.org/10.1182/blood.V128.22.1784.1784

Published: 2016

Journal Articles

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Alina Danu, MD, Sophie Cotteret, PhD, Ludovic Lacroix, Véronique Saada, PharmD, Véronique Vergé, MD, Nathalie Auger, Julien Lazarovici, MD, Edith Carton, Jonathan Farhi, Khalil Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Jean-Marie Michot, MD, Vincent Ribrag, MD

Blood (2016) 128 (22): 5638.

https://doi.org/10.1182/blood.V128.22.5638.5638

Published: 2016

Journal Articles

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Vincent Ribrag, MD, Khalil Saleh, MD, Alina Danu, MD, Serge Koscielny, Sylvain Pilorge, MD, Cristina castilla-Lorente, MD, David Ghez, Ph DMD, Julien Lazarovici, MD, Jean-Marie Michot, MD, Valerie Lapierre, PhD MD, Kamelia Alexandrova, Julia Arfi-Rouche, MD, Jean-Henri Bourhis, MD PhD

Blood (2016) 128 (22): 4648.

https://doi.org/10.1182/blood.V128.22.4648.4648

Published: 2016

Journal Articles

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Christophe Willekens, MD, Jean-Baptiste Micol, MD, Vianney Poinsignon, Cyril Quivoron, Véronique Saada, Sophie Broutin, Marie Terroir-Cassou-Mounat, David Ghez, Jean-Henri Bourhis, MD PhD, Jacques Bosq, MD, Vincent Ribrag, MD, Angelo Paci, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3835.

https://doi.org/10.1182/blood.V126.23.3835.3835

Published: 2015

NARROW

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

B-Cell Prolymphocytic Leukemia, a Rare Lymphoproliferative Disorder: Analysis of 35 Cases, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma

Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only